Life Sciences Tools and Services
Company Overview of Yeda Research & Development Co. Ltd
Yeda Research & Development Co. Ltd., a technology transfer company, markets and commercializes the intellectual property developed by the scientists in the Weizmann Institute of Science. The company identifies and assesses research projects with commercial potential; protects the intellectual property of the institute and its scientists; creates business relationships and licenses the institute’s inventions and technologies to the industry; and channels funding from industry to research projects. Its portfolio covers a range of natural sciences, including biotechnology, pharmaceuticals, and diagnostics; bioinformatics, proteomics, biomatics, and system biology; medical devices; renewable en...
Weizman Institue of Science
Gilbert de Botton Building (Building No. 5)
P.O. Box 95
Founded in 1959
Key Executives for Yeda Research & Development Co. Ltd
Chief Intellectual Property Officer
Compensation as of Fiscal Year 2016.
Yeda Research & Development Co. Ltd Key Developments
Galmed Pharmaceuticals and Weizmann Institute Collaborate to Research Impact of Aramchol on Gut Microbiome
Jun 30 16
Galmed Pharmaceuticals signed an agreement with Yeda Research and Development. The pact is intended to assess the effects of the company's proprietary molecule, Aramchol, on the human gut microbiome. Under the terms, the company has a right to enter into exclusive negotiations with Yeda to complete a license deal to commercialize a diagnostic and/or prognostic tool for Aramchol and/or a diagnostic and/or prognostic tool in the field of liver disease.
TxCell SA Enters Agreement with Yeda Research and Development Co
Jun 23 16
TxCell SA reported the grant by the European Patent Office of the patent covering all redirected, genetically engineered T regulatory cells (CAR-Tregs) and their use in the suppression of autoimmune and inflammatory diseases. As a result, TxCell has exercised its option and signed an exclusive worldwide licensing agreement with Yeda Research and Development Co. Ltd. TxCell originally signed the option agreement with Yeda Research and Development Co. Ltd. in June 2015. As per the terms of the current license agreement, TxCell said that it has now been granted exclusive rights to, notably, develop and commercialize CAR-Treg products for the treatment of autoimmune and inflammatory diseases, as covered by the patent family. The company noted that the CAR-Treg patent family covered under its licensing agreement with Yeda originated in the Weizmann Institute of Science laboratory of Professor Zelig Eshhar, who pioneered the CAR (Chimeric Antigen Receptor) approach. Professor Eshhar was the first scientist to demonstrate the therapeutic potential of CAR-Treg cells in preclinical models of intestinal inflammation. TxCell recently appointed Professor Eshhar as the Chairman of its newly established Scientific Advisory Board (SAB).
Stockton Israel and Yeda Research and Development Company Ltd. Sign an Extension to its Joint Research Agreement
Jun 6 16
Stockton Israel signed an extension to its joint research agreement with Yeda Research and Development Company Ltd., for the joint research with Prof. Assaf Aharoni'sPlant Sciences laboratory. The agreement includes an option for an exclusive, royalty bearing license to develop new Bioinsecticide. Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science, Rehovot, Israel. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries